# A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines

> **NCT05463965** · PHASE3 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 605 (actual)

## Conditions studied

- Moderate to Severe Glabellar Lines

## Interventions

- **BIOLOGICAL:** QM1114-DP
- **BIOLOGICAL:** OnabotulinumtoxinA
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05463965
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-29
- **Primary completion:** 2023-01-29
- **Final completion:** 2023-06-15
- **Target enrollment:** 605 (ACTUAL)
- **Last updated:** 2023-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05463965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05463965, "A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05463965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*